Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2021 / N 4

Возможности репозиционирования флувоксамина для терапии COVID-19: обзор механизмов действия, исследований и рекомендаций
О.Н. Ткачёва, Ю.В. Котовская, М.А. Чердак, Э.А. Мхитарян, И.Г. Никитин


References

1. Prasad A, Prasad M. Single virus targeting multiple organs: what we know and where we are heading? Frontiers in Medicine (Lausanne) 2020;7:370.
2. Phadke M, Saunik S. COVID-19 treatment by repurposing drugs until the vaccine is in sight. Drug Development Research 2020 Aug;81(5):541-3.
3. Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. European Archives of Psychiatry and Clinical Neuroscience 2021 Mar;271(2):249-58.
4. Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 2021 Apr;76(4):412-20.
5. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Critical Care (London, England) 2020 Jun;24(1):360.
6. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews. Immunology 2020 Jun;20(6):363-74.
7. Huertas A, Montani D, Savale L, Pichon J, Tu L, Parent F, Guignabert C, Humbert M. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? The European Respiratory Journal 2020 Jul;56(1):2001634.
8. Yermilov VV, Barkanov VB, Barkanova ON, Dorofeyev NA, Filatov VE. Clinical and anatomical features of SARS-COV-2 with acute hemorrhagic necrotizing encephalopathy. Arkhiv Patologii 2021;83(1):35-43 (In Russian).
9. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet. Psychiatry 2020 Jul;7(7):611-27.
10. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T. Neurological associations of COVID-19. The Lancet. Neurology 2020 Sep;19(9):767-83.
11. Hashimoto K. Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention. European Archives of Psychiatry and Clinical Neuroscience 2021 Mar; 271(2):387-9.
12. Zimmer A, Youngblood A, Adnane A, Miller BJ, Goldsmith DR. Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: a review of the literature and recommendations for the COVID-19 pandemic. Brain, Behavior and Immunity 2021 Jan;91:756-70.
13. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet. Psychiatry 2021 May;8(5):416-27.
14. Liu L, Ni SY, Yan W, Lu QD, Zhao YM, Xu YY, Mei H, Shi L, Yuan K, Han Y, Deng JH, Sun YK, Meng SQ, Jiang ZD, Zeng N, Que JY, Zheng YB, Yang BN, Gong YM, Ravindran AV, Kosten T, Wing YK, Tang XD, Yuan JL, Wu P, Shi J, Bao YP, Lu L. Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: a systematic review, meta-analysis and call for action. EClinicalMedicine 2021 Oct;40:101111.
15. Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, Borsini A, Casanova Dias M, Tamouza R, Leboyer M, Benros ME, Branchi I, Fusar-Poli P, De Picker LJ. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. The Lancet. Psychiatry 2021 Sep;8(9):797-812.
16. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific Reports 2021 Aug;11(1):16144.
17. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 Accessed 2021 Dec 21.
18. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021 Aug;38:101019.
19. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infectious Diseases (London, England) 2021 Oct;53(10):737-54.
20. Asadi-Pooya AA, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, Barzegar Z, Kabiri M, Zeraatpisheh Z, Farjoud-Kouhanjani M, Jafari A, Sasannia F, Ashrafi S, Nazeri M, Nasiri S, Shahisavandi M. Long COVID syndrome-associated brain fog. Journal of Medical Virology 2021 Oct 21;10.1002/jmv.27404. doi: 10.1002/jmv.27404. Online ahead of print.
21. Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI. An update of anti-viral treatment of COVID-19. Turkish Journal of Medical Sciences 2021 Dec;51(SI-1):3372-90.
22. Cheng Q, Chen J, Jia Q, Fang Z, Zhao G. Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. Aging (Albany, NY) 2021 Sep;13(18):21866-902.
23. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O’Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d’Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020 Jul;583(7816):459-68.
24. Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. European Archives in Psychiatry and Clinical Neuroscience 2021 Mar;271(2):249-58.
25. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012 Apr;78(14):1096-9.
26. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatric Disease and Treatment 2007 Aug;3(4):495-500.
27. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. International Journal of Biological Sciences 2014 Jun;10(7):654-63.
28. Szabo A, Kovacs A, Frecska E, Rajnavolgyi E. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One 2014 Aug;9(8):e106533.
29. Medvedev VE. Sigma receptors: their role in the treatment of affective disorders. Neurology, Neuropsychiatry, Psychosomatics 2012;4(2):105 (In Russian).
30. Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science Translational Medicine 2019 Feb;11(478):eaau5266.
31. Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, Tencomnao T. Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the sigma-1 receptor and autophagy. Expert Opinion on Therapeutic Targets 2021 Jun;25(6):435-49.
32. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biological Psychiatry 2007 Oct;62(8):878-83.
33. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. European Journal of Pharmacology 2014 Mar;727:167-73.
34. Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, Ghanbari A. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Scientific Reports 2017 Jul;7(1):4923.
35. Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iranian Journal of Basic Medical Sciences 2016 Sep;19(9):977-84.
36. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Frontiers in Pharmacology 2021 Apr;12:652688.
37. Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Network Open 2021 Nov;4(11):e2136510.
38. Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Molecular Psychiatry 2021 Oct 4;1-8. doi: 10.1038/s41380-021-01309-5. Online ahead of print.
39. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects – an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. European Journal of Clinical Pharmacology 2000 May;56(2):123-7.
40. Anderson GM. Fluvoxamine, melatonin and COVID-19. Psychopharmacology 2021 Feb;238(2):611.
41. Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Fluvoxamine versus other anti-depressive agents for depression. The Cochrane Database of Systematic Reviews 2010 Mar 17;(3):CD006114.
42. Liu X, Li X, Zhang C, Sun M, Sun Z, Xu Y, Tian X. Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: a meta-analysis. Medicine (Baltimore) 2018 Jul;97(28):e11547.
43. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2010 Aug;15(8):850-5.
44. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020;324(22):2292-300.
45. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infectious Diseases 2021 Feb;8(2):ofab050.
46. Reis G, Dos Santos Moreira-Silva EA, Medeiros Silva DC, Thabane L, Milagres AC, Ferreira TS, Quirino Dos Santos CV, de Souza Campos VH, Ribeiro Nogueira AM, Guimaraes de Almeida APF, Callegari ED, de Figueiredo Neto AD, Monteiro Savassi LC, Campos Simplicio MI, Oliveira LBRR, Harari O, Forrest JI, Sprague HRS, McKay P, Glushchenko AV, Rayner GR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet. Global Health 2022 Jan;10(1):e42-e51.
47. Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, Likic R. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. British Journal of Clinical Pharmacology 2021 Nov 1;10.1111/bcp.15126. doi: 10.1111/bcp.15126. Online ahead of print.
48. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available from: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf Accessed 2021 Dec 21.
49. Front Line COVID-19 Critical Care Alliance. Prevention & Treatment Protocols for COVID-19. I-RECOVER Management Protocol for Long Haul COVID-19 Syndrome (LHCS). Available from: https://covid19criticalcare.com/covid-19-protocols/i-recover-protocol/ Accessed 2021 Dec 21.
50. BJC HealthCare. COVID-19 Adult Treatment Guidance. Updated October 15, 2021. Available from: https://fpp.wustl.edu/wp-content/uploads/2021/01/BJC-WashU-COVID-19-Treatment-Guidance-Jan-15-2021-Final.pdf Accessed 2021 Dec 21.
51. Bueno-Notivol J, Gracia-García P, Olaya B, Lasheras I, López-Antón R, Santabárbara J. Prevalence of depression during the COVID-19 outbreak: a meta-analysis of community-based studies. International Journal of Clinical and Health Psychology 2021 Jan-Apr;21(1):100196.
52. Mosolov SN. Problems of mental health in the situation of COVID-19 pandemic. SS Korsakov Journal of Neurology and Psychiatry 2020;120(5):7-15 (In Russian).
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]